Stockscreener 앱 받기
5.90
2.80%
-0.17
시간 외 거래:
5.90
전일 마감가:
$6.07
열려 있는:
$6.07
하루 거래량:
2.72M
Relative Volume:
2.00
시가총액:
$380.41M
수익:
$202.09M
순이익/손실:
$-61.69M
주가수익비율:
-5.463
EPS:
-1.08
순현금흐름:
$-35.64M
1주 성능:
-35.52%
1개월 성능:
-36.29%
6개월 성능:
-55.00%
1년 성능:
-54.72%
1일 변동 폭
$5.86
$6.0796
1주일 범위
$5.85
$9.3475
52주 변동 폭
$5.85
$17.82
Evolus Inc Stock (EOLS) Company Profile
명칭
Evolus Inc
전화
(949) 284-4555
주소
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
EOLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
5.90 | 412.05M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
147.35 | 64.93B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 45.07B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.54 | 41.53B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.37 | 18.37B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.50 | 13.68B | 2.99B | 1.21B | 1.13B | 25.06 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 다운그레이드 | Needham | Buy → Hold |
| 2025-04-17 | 개시 | BTIG Research | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 개시 | Needham | Buy |
| 2022-05-12 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-04-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-24 | 다운그레이드 | Truist | Buy → Hold |
| 2020-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-02-06 | 재개 | Mizuho | Buy |
| 2019-11-26 | 개시 | SVB Leerink | Outperform |
| 2019-09-05 | 재개 | Mizuho | Buy |
| 2019-06-28 | 개시 | Wells Fargo | Market Perform |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2019-01-29 | 개시 | Stifel | Buy |
모두보기
Evolus Inc 주식(EOLS)의 최신 뉴스
Analysts Just Slashed Their Evolus, Inc. (NASDAQ:EOLS) EPS Numbers - simplywall.st
Evolus (EOLS): Navigating Earnings Revisions and Long-Term Potential in the Aesthetic Medicine Sector - AInvest
Evolus plunges after Q2 miss, guidance cut; Needham downgrades - MSN
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
When Will Evolus, Inc. (NASDAQ:EOLS) Turn A Profit? - 富途牛牛
Evolus, Inc. Faces Financial Uncertainty Due to Consumer Spending Risks and Economic Volatility - AInvest
Evolus Receives Buy Rating from Leerink Partners - AInvest
Evolus, Inc. Advances Safety Study of NUCEIVA for Glabellar Lines - TipRanks
A Quick Look at Today's Ratings for Evolus(EOLS.US), With a Forecast Between $18 to $20 - 富途牛牛
Evolus, Inc. (NASDAQ:EOLS) Q2 2025 Earnings Call Transcript - Insider Monkey
Evolus, Inc. Faces Financial Instability Amid Economic Uncertainty and Consumer Spending Risks - TipRanks
Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates - MSN
Evolus, Inc. Earnings Call: Mixed Sentiments and Strategic Goals - TipRanks
Evolus Appoints New Principal Financial Officer - MSN
Evolus 2025 Q2 Earnings Misses Targets, Net Loss Widens by 51% - AInvest
Evolus stock down on Q2 miss; Needham downgrades (EOLS:NASDAQ) - Seeking Alpha
Evolus, Inc. shares fall 30.53% intraday after disappointing Q2 earnings and lowered 2025 sales target. - AInvest
Evolus Reports Q2 Revenue of $69.4mln, Misses Estimates by 15.4%, Lowers Full-Year Guidance - AInvest
Evolus stock price target lowered to $20 by H.C. Wainwright on market headwinds - Investing.com Canada
Evolus price target lowered to $18 from $21 at BTIG - TipRanks
Evolus: HC Wainwright Maintains Buy, PT Down to $20 from $27 - AInvest
Evolus stock price target lowered to $18 at BTIG on Q2 revenue miss - Investing.com India
Evolus Stock Plunges 25.14% on Disappointing Earnings - AInvest
Evolus Q2 2025 slides: Filler launch drives market expansion despite earnings miss - Investing.com Nigeria
Evolus, Inc. Reports Q2 2025 Financial Results - TipRanks
Evolus outlines $700M 2028 revenue target and cost realignment amid market softness - MSN
Evolus Sees Steady Gains And Eyes Profit Next Year - Finimize
Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates - BioSpace
Evolus, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:EOLS) - Seeking Alpha
Earnings call transcript: Evolus Q2 2025 misses EPS and revenue forecasts - Investing.com Canada
Evolus, Inc. SEC 10-Q Report - TradingView
Evolus earnings missed by $0.17, revenue fell short of estimates - Investing.com Australia
Evolus reports Q2 EPS (27c), consensus (9c) - TipRanks
RENEW 8-K: Ninth SPAC Extension Adds $250k to Trust, Deadline Sep 5 2025 | EOLS SEC FilingForm 8-K - Stock Titan
Evolus, Inc. Advances NUCEIVA Safety Study: Key Insights for Investors - TipRanks
Is it the right time to buy Evolus Inc. stockGet expert advice on portfolio optimization - Jammu Links News
What institutional investors are buying Evolus Inc. stockMaximize returns with timely market signals - Jammu Links News
What drives Evolus Inc. stock priceUnlock exclusive stock analysis for investors - Jammu Links News
Is Evolus Inc. a good long term investmentUnlock powerful market trend analysis - Jammu Links News
What are Evolus Inc. company’s key revenue driversGrow your portfolio with growth-oriented stocks - Jammu Links News
How strong is Evolus Inc. company’s balance sheetBreakout stock performance - Jammu Links News
How many analysts rate Evolus Inc. as a “Buy”Capitalize on momentum-driven opportunities - Jammu Links News
What is the dividend policy of Evolus Inc. stockTrack top-performing stocks effortlessly - Jammu Links News
Should I hold or sell Evolus Inc. stock in 2025Exceptional financial outcomes - Jammu Links News
Published on: 2025-08-03 12:33:40 - Jammu Links News
Is Evolus Inc. stock overvalued or undervaluedFree Real-Time Stock Data - Jammu Links News
How volatile is Evolus Inc. stock compared to the marketExceptional profit potential - Jammu Links News
When is Evolus Inc. stock expected to show significant growthSky-high return potential - Jammu Links News
What is Evolus Inc. company’s growth strategyBreakthrough stock performance - Jammu Links News
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins - BioSpace
Evolus, Inc. shares fall 1.23% after-hours following publication of independent study in JAMA Dermatology. - AInvest
Evolus Inc (EOLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.43%
0.47%
자본화:
|
볼륨(24시간):